

# Obesity Cost Soars to \$147 Billion a Year

BY HEIDI SPLETE

WASHINGTON — The health cost of obesity in the United States jumped from \$74 billion in 1998 to approximately \$147 billion (inflation adjusted) today, based on data from a study conducted by the Centers for Disease Control and Prevention and the Research Triangle Institute. The data were presented last month at the CDC's inaugural Weight of the Nation conference on obesity.

"Obesity affects every body system," Dr. Thomas R. Frieden, director of the CDC, said during opening remarks at the conference.

Obesity accounted for 6.5% of overall annual medical costs in the United States in 1998, but that proportion increased to 9.1% by 2006, said the study's lead author, Eric Finkelstein, Ph.D., of the independent Research Triangle Institute.

The annual cost of medical care per adult in the United States is 41% less for a normal-weight individual than for an obese individual, Dr. Finkelstein said. In this study, obesity was defined as a body mass index of 30 kg/m<sup>2</sup> or higher, and normal weight was defined as 18.5-25 kg/m<sup>2</sup>.

Prescription drugs are among the top contributors to the costs of obesity, Dr. Finkelstein said. In 2006, across all insurance payers, the average annual prescription drug cost for a normal-weight individual was \$707, compared with \$1,275 for an obese individual. This difference represents an 80% increase in drug costs for the obese, Dr. Finkelstein said. The data were collected from annual Medical Expenditure Panel Surveys, which are nationally representative surveys of medical expenses for the civilian, noninstitutionalized U.S. population. The complete data were published online on July 27 in the journal *Health Affairs* (doi: 10.1377/hlthaff.28.5.w822).

If the obesity prevalence had remained the same between 1998 and 2006, 2006 medical costs in the United States would have been approximately \$40 billion less, Dr. Finkelstein emphasized.

The study results were limited by the reliance on self-reports of body mass index, Dr. Finkelstein noted. The study examined only aggregate health costs and did not look at disease-specific costs, but "diabetes is one of the largest drivers of health care costs," he said.

At a media briefing, Dr. Frieden said that the most effective strategies to reduce obesity and its associated costs in the United States may involve community intervention rather than clinical intervention. But physicians have a responsibility to promote healthy living in their communities, as well as to encourage patients' weight-loss efforts in a clinical practice setting, he added.

The study was sponsored in part by the CDC. ■

# CDC Urges Communities to Combat Obesity

BY HEIDI SPLETE

WASHINGTON — Curbing the obesity epidemic requires community intervention, Dr. Thomas R. Frieden, director of the Centers for Disease Control and Prevention, said at the CDC's Weight of the Nation conference.

"The only way on a societal basis to reduce the prevalence of obesity is through community action, not through individual clinical interven-

tions," Dr. Frieden said in a press conference.

"We got to this stage in the [obesity] epidemic because of a change in our environment," he said. "Only a change in our environment again will allow us to get back to a healthier place."

To help communities respond to the obesity epidemic, the CDC launched Common Community Measures for Obesity Prevention. As part of this project, the CDC convened a panel of

experts in a variety of areas including nutrition, urban planning, and physical activity, as well as obesity prevention. The complete recommendations, along with supporting evidence and suggestions for implementation, were published in the *Morbidity and Mortality Weekly Report* (2009:58 [RR-7]:1-26).

"We can't wait for the best possible evidence; we have to act on the best available evidence," explained Dr. William



**Mealtime therapy matters inside the body. But it first needs to fit your patient's life.**



Achieving mealtime control takes more than insulin alone. That's why the Humalog® 3-Part Approach provides a combination of products, pens, and tools designed to help fit mealtime insulin into your patient's life. To find out more, visit [www.humalog.com](http://www.humalog.com).

**Humanly possible.**

*Humalog*

insulin lispro injection (rDNA origin)

For additional safety profile and other important prescribing considerations, see the accompanying Brief Summary of full Prescribing Information.